| Cat. No. |
Product Name |
Information |
| PC-61582 |
PF-232798
CCR5 antagonist
|
PF-232798 (PF-00232798) is a potent CCR5 antagonist with IC50 of <0.1 nM in gp160 fusion assay, exhibits potent broad-spectrum anti-HIV-1 activity. |
| PC-61576 |
INCB10820
Dual CCR2/5 antagonist
|
INCB10820 (PF-4178903) is a potent, selective, orally bioavailable dual CCR2 and CCR5 antagonist with binding IC50 of 3.0 nM and 5.3 nM, respectively. |
| PC-61559 |
PF-04634817 succinate
CCR2/CCR5 inhibitor
|
PF-04634817 succinate is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist with IC50 of 20.8 nM (human and rodent CCR2), 470 nM (rat CCR5). |
| PC-61558 |
PF-04634817
CCR2/CCR5 antagonist
|
PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist with IC50 of 20.8 nM (human and rodent CCR2), 470 nM (rat CCR5). |
| PC-61557 |
PF-04136309
CCR2 antagonist
|
PF-4136309 (INCB8761) is a potent, selective, competitive, reversible full CCR2 antagonist with IC50 of 2-5 nM. |
| PC-61475 |
Ladarixin sodium
CXCR1/2 inhibitor
|
Ladarixin sodium (DF-2156) is an allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM. |
| PC-61474 |
Ladarixin
CXCR1/CXCR2 inhibitor
|
Ladarixin (DF 2156) is an allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM. |
| PC-61471 |
AZD8309
CXCR2 antagonist
|
AZD8309 is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils. |
| PC-61467 |
ST 016907
CCR4 antagonist
|
ST 016907 is a potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo. |
| PC-61466 |
AF-399 42016530
CCR4 antagonist
|
AF-399/42016530 is a potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo. |
| PC-61317 |
LY-2510924
CXCR4 inhibitor
|
LY-2510924 (LY2510924) is a potent and selective, cyclic peptide CXCR4 antagonist with IC50 of 0.079 nM, without apparent agonist activity. |
| PC-61294 |
KRH-3955
|
KRH-3955 is a potent, selective, orally bioavailable inhibitor of CXCR4 that efficiently inhibits SDF-1α binding to CXCR4 with IC50 of 0.61 nM. |
